Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy

Tristan D Yan, Oswald A Stuart, Dal Yoo, Paul H Sugarbaker, Tristan D Yan, Oswald A Stuart, Dal Yoo, Paul H Sugarbaker

Abstract

The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination from gastrointestinal and ovarian cancers. Cancer progression causes peritoneal implants to be distributed throughout the abdominopelvic cavity. These nodules plus the ascitic fluid result in abdominal distension. As the disease progresses, these tumors cause intestinal obstruction leading to debilitating symptoms and a greatly impaired quality of life. In the past, the prognosis of patients with peritoneal surface malignancy was regarded dismal and cure was not an option. Recently, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an improved survival in selected patients with this disease. To date, multiple different treatment regimens of perioperative intraperitoneal chemotherapy have been used. This review focuses on the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.

References

    1. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, Sato T, Fushida S, Nishimura G, Miwa K, Miyazaki I, Murakami K, Katayama K, Yamaguchi A. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg. 1999;84:60–66.
    1. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum. 2000;43:1341–1346. doi: 10.1007/BF02236627.
    1. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–1593. doi: 10.1046/j.1365-2168.2000.01571.x.
    1. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239–243. doi: 10.1053/ejso.2000.1038.
    1. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–76. doi: 10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>;2-9.
    1. Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–984. doi: 10.1016/S0959-8049(01)00058-2.
    1. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. American Surgeon. 2001;67:999–1003.
    1. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surgery. 2001;88:458–463. doi: 10.1046/j.1365-2168.2001.01701.x.
    1. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, Manns M, Klempnauer J. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol. 2001;27:286–290. doi: 10.1053/ejso.2000.1095.
    1. Butterworth SA, Panton ON, Klaassen DJ, Shah AM, McGregor GI. Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei. Am J Surg. 2002;183:529–532. doi: 10.1016/S0002-9610(02)00843-7.
    1. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–621. doi: 10.1016/S1055-3207(03)00045-0.
    1. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567. doi: 10.1200/JCO.2003.04.150.
    1. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743. doi: 10.1200/JCO.2003.04.187.
    1. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004;14:35–41. doi: 10.1111/j.1048-891x.2004.14008.x.
    1. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of 506 patients. J Clin Oncol. 22:3284–3292. doi: 10.1200/JCO.2004.10.012. 2004 Aug 15.
    1. Torres IL, Litterst CL, Guarino AM. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology. 1978;17:330–340.
    1. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979;39:2264–2268.
    1. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10:463–468. doi: 10.1245/ASO.2003.08.006.
    1. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41:147–154. doi: 10.1007/s002800050721.
    1. Los G, Smals OAG, van Vugt MJH. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992;52:1252–1258.
    1. Sugarbaker , Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P. Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res. 1990;50:5790–5794.
    1. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Progress in management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol.
    1. Jacquet P, Stuart OA, Chang D, Sugarbaker PH. Effects of intraabdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs. 1996;7:596–603.
    1. Sugarbaker PH. In: Early postoperative intraperitoneal Adriamycin as an adjunctive treatment for advanced gastric cancer with lymph node or serosal invasion. Sugarbaker PH, editor. Management of Gastric Cancer. Kluwer: Boston; 1991. pp. 277–284.
    1. Sugarbaker PH. In: Early postoperative intraperitoneal Adriamycin as an adjunctive treatment for visceral and retroperitoneal sarcoma. Sugarbaker PH, editor. Management of Gastric Cancer Kluwer: Boston; 1996. pp. 7–14.
    1. Yan TD, Stuart OA, Sugarbaker PH. Pharmacokinetic profile of heated intraoperative intraperitoneal doxorubicin for diffuse malignant peritoneal mesothelioma. (Submitted for publication)
    1. Los G, van Vugt MJH, den Engelse, Pinedo HM. Effects of the temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol. 1993;46:1229–1237. doi: 10.1016/0006-2952(93)90472-9.
    1. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290:871–880.
    1. Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol. 2003;29:261–265. doi: 10.1053/ejso.2002.1397.
    1. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. (Submitted to publication)
    1. Sugarbaker PH. The natural history, gross pathology and histopathology of appendiceal epithelial neoplasms. Eur J Surg Oncol.
    1. van Ruth S, Verwaal VJ, Zoetmulder FAN. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–780. doi: 10.1016/S1055-3207(03)00031-0.
    1. Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solutions in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol. 11:1–6. 2005 Aug.
    1. Sugarbaker PH, Chang D. Epithelial appendiceal neoplasm with peritoneal dissemination. Update on a comprehensive management strategy in 803 patients with pseudomyxoma peritonei. (Submitted for publication)
    1. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–367.
    1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from nongynecologic malignancies: results of the EVOCAPE 1 multi-centeric prospective study. Cancer. 2000;88:58–63. doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>;2-O.
    1. Le vi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-flurouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer. 1999;85:2532–2540. doi: 10.1002/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>;2-1.
    1. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomized trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;35:1407–1412. doi: 10.1016/S0140-6736(98)03085-2.
    1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
    1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 2000;355:1041–1047. doi: 10.1016/S0140-6736(00)02034-1.
    1. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147.
    1. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12:755–769. doi: 10.1016/S1055-3207(03)00051-6.
    1. Elias D, Raynard B, Farkhondeh F. Peritoneal carcinomatosis of colonrectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. (submitted for publication)
    1. Gomes da Silva RG, Sugarbaker PH. Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. (Submitted for publication)
    1. Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy and perioperative intraperitoneal chemotherapy: evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003;21:233–248. doi: 10.1002/ssu.10042.
    1. Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura K, Sawa T, Katayama K, Tanaka S, Hirono Y, Miwa K. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg. 1995;19:450–455. doi: 10.1007/BF00299188.
    1. Yonemura Y, Bandou E, Sawa T. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. (submitted for publication)
    1. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer. 1993;71:517–523.
    1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6. doi: 10.1056/NEJM199601043340101.
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200. doi: 10.1200/JCO.2003.02.153.
    1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:77–79. doi: 10.1056/NEJMoa052985.
    1. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999;15:79–107. doi: 10.1080/026567399285765.
    1. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg. 2001;25:985–990. doi: 10.1007/s00268-001-0067-7.
    1. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;10:2727–2730.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner